Section Arrow
Quote
EYPT.NASDAQ
- EyePoint Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/18 19:01 EST
After Hours
Last
 14.17
+0.21 (+1.50%)
Bid
13.8
Ask
14.27
High 14.17 
Low 13.8 
Volume 19309 
Regular Hours
Last
 13.96
+0.825 (+6.28%)
Day High 
14.551 
Prev. Close
13.135 
1-M High
13.34 
Volume 
2.19M 
Bid
13.8
Ask
14.27
Day Low
12.95 
Open
13.14 
1-M Low
9.65 
Market Cap 
1.09B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.69 
20-SMA 11.87 
50-SMA 12.75 
52-W High 14.91 
52-W Low 3.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.00/-2.83
Enterprise Value
1.11B
Balance Sheet
Book Value Per Share
2.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.27M
Operating Revenue Per Share
0.51
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CANFCan-Fite BioPharma Ltd0.3801+0.0181+5.00%-- 
After Hours 0.4047 +0.0246 +6.47%
ASBPAspire Biopharma Holdings Inc.0.1057+0.0144+15.77%-- 
After Hours 0.1033 -0.0024 -2.27%
OLMAOlema Pharmaceuticals20.14+11.62+136.38%-- 
After Hours 19.1 -1.04 -5.16%
CMNDClearmind Medicine0.2164-0.0605-21.85%0.16PE
After Hours 0.2311 +0.0147 +6.79%
APLTApplied Therapeutics0.2984+0.0142+5.00%-- 
After Hours 0.29 -0.0084 -2.82%
Quotes are at least 15-min delayed：2025/11/18 19:01 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.